デュシェンヌ型筋ジストロフィー治療薬市場：薬剤タイプ、投与方法、最終用途別-2024-2030年の世界予測

デュシェンヌ型筋ジストロフィー治療薬市場規模は2023年に15億7,000万米ドルと推定され、2024年には17億米ドルに達し、CAGR 8.61％で2030年には28億米ドルに達すると予測されます。

デュシェンヌ型筋ジストロフィー（DMD）治療薬市場は、進行性の筋変性と筋力低下を特徴とする遺伝性疾患であるDMDの治療に特化した医薬品の販売、開拓、生産に焦点を当てています。遺伝子研究の進歩やDMDの遺伝的基盤の解明における画期的な進歩により、より的を絞った効果的な治療が行われるようになり、市場の拡大に寄与しています。世界のヘルスケア支出の増加により、DMD治療へのアクセスが向上し、市場拡大に寄与しています。政府や非営利団体による資金援助やイニシアチブが研究開発努力を後押しし、DMD治療薬の市場導入を促進しています。医薬品承認と市場イントロダクションのための厳しい規制要件は、革新的治療へのアクセスを遅らせる可能性があり、市場領域における課題となっています。さらに、CRISPR/Cas9やその他の遺伝子編集ツールなどの遺伝子編集技術の進歩は、デュシェンヌ型筋ジストロフィーの根治治療の可能性を提供しています。個人の遺伝子プロファイルに合わせた個別化医療アプローチの開発は、有効性を向上させ副作用を最小限に抑え、市場成長の機会を生み出す可能性があります。

薬剤の種類デュシェンヌ型筋ジストロフィーの標的治療薬としてカシメルセンへの嗜好が高まる

カシメルセンは、エクソン45スキッピングによる変異が確認された患者のDMD治療薬として承認されています。カジメルセンに対するこの必要性に基づく優遇措置は、特定の遺伝的体質を持つ患者にとって極めて重要であり、標的治療の選択肢を提供するものです。デフラザコートは、特定の遺伝子変異に関係なく、幅広い患者においてDMDの進行を遅らせ、筋力を向上させる効果を保証します。デランジストロゲン・モキセパルボベック（Roctavian）遺伝子治療は、DMDの原因となる遺伝子欠損を直接修正するアプローチが有効な患者を対象としています。エテプリルセン（エクソンディス51）は、エクソン51のスキッピングによりDMD遺伝子の変異が確認されたDMD患者に適しています。ゴロジルセンは、ニッチな患者グループのニーズに応え、エクソン53スキップに適応のある特定の遺伝子変異に的を絞った遺伝子治療を提供します。Viltolarsenは、エクソン53スキッピングが適応となるDMD患者を対象に承認されており、特定の遺伝子変異を標的とすることで、罹患患者にプレシジョン・メディシン・アプローチを提供します。

最終用途：外来でのDMD治療薬の採用増加

外来診療センターとも呼ばれる外来センターは、入院を必要としない医療サービスを患者に提供します。外来センターは、その利便性と費用対効果から、定期検診、診断、DMDのような慢性疾患の管理にますます好まれています。在宅ケア施設は、DMDの薬物治療を含むヘルスケアサービスを患者の自宅で受けたいという希望に応えるもので、急成長している分野です。在宅ケアでは、継続的で個別化されたケアとDMD治療薬の投与が患者の自宅で快適に行われます。

地域別インサイト

米国とカナダは、デュシェンヌ型筋ジストロフィー（DMD）治療薬の開発に携わる主要企業が強い存在感を示しており、極めて重要な地域です。南北アメリカ地域の特徴は、消費者の認知度の高さ、研究開発への多額の投資、有利な政府政策です。米国は画期的な治療法の開発において重要な地位を占めており、革新的なDMD治療法について複数の特許を申請しています。カナダは、政府による強力な支援と官民パートナーシップを示し、市場の成長を促進しています。欧州連合（EU）諸国は、DMD治療薬開発に対する規制当局の支援に関して最前線にあり、研究や治療へのアクセスを支援するいくつかのイニシアチブを有しています。EMEA地域では特許活動が活発で、いくつかの国が発見に貢献しています。中東地域は、市場規模は小さいもの、投資が増加し、認知度が高まっています。アフリカはヘルスケア・インフラと治療アクセスに関する課題に直面しており、国際的なパートナーシップと投資を通じて成長の可能性を示しています。アジア太平洋地域、特に中国、日本、インドは、DMD治療薬市場で大きく成長しています。APAC諸国における市場成長は、認知度の向上、政府のイニシアティブ、ヘルスケアインフラの改善に起因しています。APAC諸国における調査と投資は活発で、日本は革新的な治療法と特許申請でリードしています。中国とインドは急速に調査を進め、費用対効果の高い治療法を提供しており、市場力学と顧客の購買行動に大きな影響を与えています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、デュシェンヌ型筋ジストロフィー治療薬市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、デュシェンヌ型筋ジストロフィー治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.デュシェンヌ型筋ジストロフィー治療薬市場の市場規模および予測は？

2.デュシェンヌ型筋ジストロフィー治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.デュシェンヌ型筋ジストロフィー治療薬市場の技術動向と規制枠組みは？

4.デュシェンヌ型筋ジストロフィー治療薬市場における主要ベンダーの市場シェアは？

5.デュシェンヌ型筋ジストロフィー治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • デュシェンヌ型筋ジストロフィーを含む遺伝性疾患の罹患率の増加
    • 遺伝子調査の継続的な進歩とDMDの遺伝的基礎の理解における画期的な進歩
  • 抑制要因
    • DMD薬物療法の高コスト
  • 機会
    • CRISPR/Cas9などの遺伝子編集ツールと遺伝子編集技術の進歩
    • 個人の遺伝子プロファイルに合わせた個別化医療アプローチの開発
  • 課題
    • DMD薬に関する認知度の低さと副作用
• 市場セグメンテーション分析
  • 薬剤の種類：デュシェンヌ型筋ジストロフィーの標的治療薬としてカシメルセンが人気上昇
  • 最終用途：外来センターにおけるDMD薬の採用増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 デュシェンヌ型筋ジストロフィー治療薬市場薬の種類別

• カシメルセン
• デフラザコート
• デランジストロゲンモキセパルボベック
• エテプリルセン
• ゴロディルセン
• ヴィルトラルセン

第7章 デュシェンヌ型筋ジストロフィー治療薬市場投与方法別

• オーラル
• 保護者

第8章 デュシェンヌ型筋ジストロフィー治療薬市場：最終用途別

• 外来センター
• ホームケア設定
• 病院・クリニック

第9章 南北アメリカのデュシェンヌ型筋ジストロフィー治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のデュシェンヌ型筋ジストロフィー治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのデュシェンヌ型筋ジストロフィー治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アガムリーがデュシェンヌ型筋ジストロフィーの治療薬として初の「解離性ステロイド系抗炎症薬」としてFDAの承認を取得
  • FDA、デュシェンヌ型筋ジストロフィーに対する新しいステロイド系抗炎症薬を承認
  • FDA、デュシェンヌ型筋ジストロフィーの特定患者の治療に初の遺伝子治療を承認
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET DYNAMICS
• FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 45. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 46. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 51. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 52. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 53. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 54. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 55. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 56. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 57. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 58. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 59. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 60. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 63. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 64. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 65. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 66. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 71. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 72. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 73. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 74. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 80. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 82. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 85. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 86. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 87. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 88. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 89. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 90. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 91. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 92. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 93. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 94. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 95. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 96. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 97. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 98. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 99. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 100. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 103. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 104. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 105. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 106. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 109. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 110. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 111. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 112. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 115. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 116. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 117. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 118. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 121. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 122. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 123. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 124. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 127. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 128. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 129. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 130. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 134. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 136. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 139. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 140. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 141. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 142. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 145. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 146. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 147. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 148. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 151. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 152. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 153. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 154. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 165. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 166. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 167. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 168. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 171. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 172. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 173. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 174. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 177. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 178. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 179. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 180. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 183. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 184. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 185. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 186. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 189. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 190. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 191. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 192. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 195. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 196. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 197. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 198. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 199. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 200. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 201. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 202. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 203. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 204. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 207. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 208. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 209. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 210. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 213. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 214. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 215. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 216. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 219. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 220. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 221. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 222. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 223. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 224. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 225. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 226. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 227. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 228. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 229. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 230. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 231. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 232. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 233. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 234. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 237. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 238. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 239. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 240. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 244. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 246. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 255. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 256. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 257. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 258. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 261. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 262. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 263. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 264. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 267. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 268. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 269. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 270. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 273. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 274. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 275. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 276. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 280. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 281. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
• TABLE 286. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 288. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 289. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 290. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

[182 Pages Report] The Duchenne Muscular Dystrophy Drugs Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.70 billion in 2024, at a CAGR 8.61% to reach USD 2.80 billion by 2030.

The Duchenne muscular dystrophy (DMD) drugs market focuses on the sales, development, and production of pharmaceuticals specifically aimed at treating DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. Advancements in genetic research and breakthroughs in understanding the genetic basis of DMD are leading to more targeted and effective treatments, contributing to the market expansion. Higher global healthcare expenditure enables better treatment access for DMD, contributing to market growth. Funding and initiatives by governments and non-profit organizations boost research and development efforts, enhancing the market adoption of DMD drugs. Stringent regulatory requirements for drug approval and market introduction may delay access to innovative treatments, posing challenges in the market space. Moreover, ongoing advancements in gene editing technologies such as CRISPR/Cas9 and other gene-editing tools offer potential for curative treatments of Duchenne muscular dystrophy. The development of personalized medicine approaches tailored to individual genetic profiles may improve efficacy and minimize side effects, generating opportunities for market growth.

Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy

Casimersen is approved for treating DMD in patients with a confirmed mutation due to exon 45 skipping. This need-based preference for casimersen is critical for patients with a specific genetic makeup, providing a targeted treatment option. Deflazacort ensures efficacy in delaying disease progression and improving muscle strength to slow the progression of DMD across a broad range of patients, regardless of their specific genetic mutation. Delandistrogene Moxeparvovec (Roctavian) gene therapy is designed for patients that benefit from a direct approach to correcting the gene defect responsible for DMD. Eteplirsen (Exondys 51) is preferred for DMD patients observing confirmed mutation of the DMD gene due to exon 51 skipping. Golodirsen meets the needs of a niche patient group, offering a targeted genetic treatment with a specific genetic mutation amenable to exon 53 skipping. Viltolarsen is approved for DMD patients amenable to exon 53 skipping that targets a specific genetic alteration, providing a precision medicine approach for affected patients.

End-Use: Increasing adoption of DMD drugs in ambulatory centers

Ambulatory centers, also known as outpatient care centers, provide medical services to patients that do not require hospital admission. Ambulatory center facilities have been increasingly preferred for routine check-ups, diagnosis, and the management of chronic conditions such as DMD due to their convenience and cost-effectiveness. Homecare settings represent a rapidly growing segment that caters to the preference for receiving healthcare services, including DMD drug treatments, in the patient's home. Homecare settings allow for continuous, personalized care and the administration of DMD medications in the comfort of the patient's home.

Regional Insights

In the Americas region, the United States and Canada are pivotal due to the strong presence of key players engaged in developing Duchenne Muscular Dystrophy (DMD) drugs. The Americas region is characterized by high consumer awareness, substantial investments in R&D, and favorable government policies. The United States holds a key position in developing breakthrough therapies and has several patents filed for innovative DMD treatments. Canada demonstrates strong governmental support and public-private partnerships, fostering growth in the market arena. The European Union countries are at the forefront regarding regulatory support for DMD drug development and have several initiatives supporting research and access to treatment. Patent activity is high in the EMEA region, with several countries contributing to discoveries. The Middle East region, although smaller in terms of market size, is witnessing increased investment and growing awareness. Africa faces challenges related to healthcare infrastructure and treatment access and shows potential for growth through international partnerships and investments. The Asia Pacific region, especially China, Japan, and India, has grown significantly in the DMD drugs market. The market growth in the APAC countries is attributed to increasing awareness, governmental initiatives, and improving healthcare infrastructure. Research and investment in APAC countries have been robust, with Japan leading in innovative therapies and patent filings. China and India are rapidly advancing in research and offering cost-effective treatments, significantly affecting market dynamics and customer purchasing behaviors.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Duchenne Muscular Dystrophy Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Duchenne Muscular Dystrophy Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Type
  • Casimersen
  • Deflazacort
  • Delandistrogene Moxeparvovec
  • Eteplirsen
  • Golodirsen
  • Viltolarsen

• Administration Method
  • Oral
  • Parental

• End-Use
  • Ambulatory Centres
  • Homecare Settings
  • Hospitals & Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Duchenne Muscular Dystrophy Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Duchenne Muscular Dystrophy Drugs Market?

3. What are the technology trends and regulatory frameworks in the Duchenne Muscular Dystrophy Drugs Market?

4. What is the market share of the leading vendors in the Duchenne Muscular Dystrophy Drugs Market?

5. Which modes and strategic moves are suitable for entering the Duchenne Muscular Dystrophy Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
    • 5.1.1.2. Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of DMD drug therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
    • 5.1.3.2. Development of personalized medicine approaches tailored to individual genetic profiles
  • 5.1.4. Challenges
    • 5.1.4.1. Limited awareness and side affects associated with DMD drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
  • 5.2.2. End-Use: Increasing adoption of DMD drugs in ambulatory centers
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Casimersen
• 6.3. Deflazacort
• 6.4. Delandistrogene Moxeparvovec
• 6.5. Eteplirsen
• 6.6. Golodirsen
• 6.7. Viltolarsen

7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parental

8. Duchenne Muscular Dystrophy Drugs Market, by End-Use

• 8.1. Introduction
• 8.2. Ambulatory Centres
• 8.3. Homecare Settings
• 8.4. Hospitals & Clinics

9. Americas Duchenne Muscular Dystrophy Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Agamree Receives FDA Approval as First "Dissociative Steroidal Anti-Inflammatory" to Treat Duchenne Muscular Dystrophy
  • 12.3.2. FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy
  • 12.3.3. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio